NPIL and Napo Codevelop Drug

Napo Pharmaceuticals (San Francisco) and Nicholas Piramal India Ltd. (NPIL; Mumbai) say they have entered into a plant-screening agreement to discover novel therapeutic compounds for treating diabetes. NPIL will use its screening facility and natural product chemistry expertize, along with its biological testing capabilities, to identify active compounds from Napo’s library of medicinal plant extracts from tropical regions. Napo and NPIL will jointly own all products that are developed under the agreement. “This agreement allows us to use our advanced...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers